Aug 11, 2020
Study Suggests Potential Role for Laser Ablation in Glioblastoma Treatment, Monteris Medical Announces
Jun 22, 2020
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs
Jun 22, 2020
DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II
Jun 11, 2020
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
Jun 04, 2020
Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme
Jun 04, 2020
TVAX Biomedical Receives Fast Track Designation from the FDA for Brain Cancer
Jun 02, 2020
NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer
Jun 01, 2020
BERG Presents Results of Phase 1 Clinical Study in Glioblastoma at 2020 American Society of Clinical Oncology (ASCO) Meeting
Jun 01, 2020
DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
May 29, 2020
Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020
May 27, 2020
Biotech Brief: Global Glioblastoma Multiforme Drug Market Could Exceed $1.4 Billion by 2025
May 21, 2020
I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7(TM) in Glioblastoma Multiforme
May 14, 2020
INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment
May 05, 2020
DelMar Pharmaceuticals [Nasdaq:DMPI] Provides Enrollment Update in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors
Apr 28, 2020
Denovo Biopharma To Acquire Tocagen's Entire Replicating Gene Therapy Platform and Related Assets
Apr 18, 2020
NW Bio To Discuss Projected Schedule For Data Lock, Unblinding and Top Line Data From Its Phase 3 Clinical Trial At Annual Shareholder Meeting
Apr 07, 2020
Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study
Mar 30, 2020
Diverse Biotech announces collaboration with Duke University on glioblastoma research
Mar 04, 2020
DelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors
Mar 03, 2020
Research Studies Progressing Towards New FDA Approved Treatments for Glioblastoma